Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Stock Information for Altius Renewable Royalties Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Altius Renewable Royalties Corp.

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.